logo
COVID-19 cases surge across GCC as WHO reports global rise in infections

COVID-19 cases surge across GCC as WHO reports global rise in infections

Al Arabiya4 days ago
COVID-19 infections are rising sharply across GCC countries, with Saudi Arabia and the UAE among nations driving a global surge that has pushed test positivity rates to levels not seen since July 2024, according to the latest World Health Organization report.
Global SARS-CoV-2 activity has increased significantly since mid-February 2025, with test positivity rates reaching 11 percent across 73 reporting countries - matching peaks observed during last summer's wave, the WHO report indicated.
The Eastern Mediterranean region, which includes GCC states, has emerged as a key driver of the current surge, with test positivity rates climbing from four percent in mid-March to 17 percent by late April before declining slightly to 15 percent in mid-May.
'Recent reports of increases in circulation have been observed in five countries to date, including Egypt, Kuwait, Oman, Saudi Arabia, United Arab Emirates and Pakistan,' the WHO said in its latest epidemiological update.
The surge represents a sharp reversal from the relatively low transmission levels observed in the first quarter of 2025, when many countries reported test positivity rates as low as 2 percent.
New variant
Contributing to the rise is the emergence of NB.1.8.1, a new variant under monitoring that WHO designated in early 2025. The variant, which carries mutations that may enhance transmissibility and immune evasion, now represents 10.7 percent of global sequences reported as of mid-May, up from just 2.5 percent four weeks earlier.
'Spike mutations at position 445 have been shown to enhance binding affinity to hACE2 receptor, which could increase the variant's transmissibility,' the WHO said.
The variant's rapid spread coincides with the declining circulation of LP.8.1, which had been the dominant strain since mid-March but is now being overtaken by NB.1.8.1 in many regions.
While the Eastern Mediterranean region shows concerning trends, WHO officials reported gaps in surveillance data from the region, including GCC countries.
'The reporting of COVID-19 associated hospitalizations, Intensive Care Unit (ICU) admissions, and deaths is very limited from the countries in the Eastern Mediterranean Region, the South-East Asia Region, and the Western Pacific Region and does not allow for evaluation of the impact on health systems by WHO,' the organization stated.
The WHO report highlighted persistently low vaccination rates globally, including among high-risk groups in Gulf countries. Among older adults across 75 reporting member states, just 1.68 percent had received a COVID-19 vaccine dose in 2024 through September, while uptake among healthcare workers stood at only 0.96 percent.
Regional disparities were also noted, with the Eastern Mediterranean region reporting coverage rates of less than 0.5 percent among older adults, significantly lower than the 5.1 percent achieved in Europe and 3.6 percent in the Americas.
The WHO's Technical Advisory Group on COVID-19 Vaccine Composition continues to recommend vaccines for at-risk groups, it said.
The current surge across the GCC reflects a broader pattern of renewed COVID-19 activity across multiple regions. The Western Pacific region has seen test positivity rates climb from 5 percent to 11 percent over the past month, while the South-East Asia region experienced increases from 0.5 percent to 5 percent since early April.
Unlike previous waves, the current surge lacks clear seasonal patterns, complicating efforts to predict and prepare for transmission peaks.
'Recent increases in SARS-CoV-2 activity are broadly consistent with levels observed during the same period last year, however, there still lacks a clear seasonality in SARS-CoV-2 circulation,' the WHO said.
The WHO maintains that the global public health risk associated with COVID-19 remains high, despite evidence of decreasing impact on human health compared to earlier pandemic years.
GCC countries, like other WHO member countries, are encouraged to maintain integrated surveillance systems, ensure equitable vaccine access, strengthen healthcare delivery, and enhance risk communication efforts.
The organization specifically recommends that countries 'continue to monitor and report SARS-CoV-2 activity and burden, public health and healthcare system impacts of COVID-19, strengthen genomic sequencing capacity and reporting, in particular information on SARS-CoV-2 variants.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Saudi Arabia to host 8th Global Health Exhibition in Riyadh in October
Saudi Arabia to host 8th Global Health Exhibition in Riyadh in October

Arab News

timea day ago

  • Arab News

Saudi Arabia to host 8th Global Health Exhibition in Riyadh in October

RIYADH: The eighth annual Global Health Exhibition will take place from Oct. 27 to 30 at the Riyadh Exhibition and Convention Center, the Ministry of Health said on Thursday. The aim of the event, the theme for which is 'Invest in Health,' is to help accelerate the transformation of the Kingdom's healthcare sector in line with the goals of the Vision 2030 plan for national development and diversification, the Saudi Press Agency reported, while strengthening Saudi Arabia's position as a global hub for health innovation and investment. The four-day exhibition will give health sector leaders, investors and innovators from around the world the chance to explore partnership and investment opportunities, and showcase the latest advances in healthcare technology, including developments in telemedicine, digital health and preventative care. Organizers hope this year's event will further boost momentum in the rapidly evolving Saudi health sector, building on the success of last year's exhibition that attracted more than 100,000 visitors from 80 countries, who signed deals worth more than SR50 billion ($13.3 billion). The event also reflects the Kingdom's growing influence on the global health stage, according to organizers. Recent Saudi initiatives such as the National Biotechnology Strategy and the hosting of high-profile international gatherings — including the Fourth Global High-Level Ministerial Conference on Antimicrobial Resistance in November 2024, and the upcoming 2nd annual CPHI Middle East pharmaceutical expo scheduled for December — highlight the nation's commitment to shaping the future of healthcare, they said. The exhibition aims to serve as a key platform for fostering collaborations and driving investment in technologies and initiatives that support healthier, more sustainable communities across the region and beyond, the organizers added.

SFDA approves 'Winrevair' for rare pulmonary hypertension treatment
SFDA approves 'Winrevair' for rare pulmonary hypertension treatment

Saudi Gazette

time2 days ago

  • Saudi Gazette

SFDA approves 'Winrevair' for rare pulmonary hypertension treatment

Saudi Gazette report RIYADH — The Saudi Food and Drug Authority (SFDA) has approved the registration of Winrevair (sotatercept) for the treatment of adult patients with World Health Organization (WHO) Functional Class II to III pulmonary arterial hypertension (PAH). Previously designated as an orphan drug under SFDA's Orphan Drugs Program, Winrevair addresses a critical need for patients with this life-threatening condition. PAH is characterized by the narrowing and thickening of blood vessels in the lungs, leading to symptoms such as shortness of breath, chest pain, and fatigue. Winrevair introduces a novel mechanism of action by inhibiting activin signaling, which plays a role in the thickening of pulmonary arteries. By restoring cellular growth balance, the drug improves blood flow in the lungs, reduces strain on the heart, and enhances oxygen delivery and physical endurance, thereby improving patients' quality of life. The SFDA confirmed that the drug's approval followed a comprehensive evaluation of its efficacy, safety, and quality, meeting all regulatory requirements. Clinical trials demonstrated a statistically significant and clinically meaningful reduction in the risk of disease progression or death in WHO Class II–III patients. The most common side effects reported were headache, nosebleeds, and skin itching, which were generally mild and manageable. The SFDA reiterated its commitment to supporting access to effective treatments, especially in the rare and difficult-to-treat disease space, which often suffers from limited therapeutic options. The authority's Orphan Drugs Program plays a strategic role in advancing pharmaceutical innovation and addressing unmet medical needs. Under the program, orphan drugs are defined as those intended to treat diseases affecting fewer than five individuals per 10,000 people in Saudi Arabia. The program offers benefits to pharmaceutical companies, including pre-submission meetings, priority review, and scientific consultations.

Moderna receives full US approval for COVID-19 vaccine in children 6 months and older
Moderna receives full US approval for COVID-19 vaccine in children 6 months and older

Al Arabiya

time2 days ago

  • Al Arabiya

Moderna receives full US approval for COVID-19 vaccine in children 6 months and older

The US Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, the company said on Thursday. The shot was previously available for pediatric populations under emergency use authorization. Moderna said it expects to have its updated vaccine available for eligible populations in the US for the 2025-26 respiratory virus season. Shares of the company rose 2 percent to $33.45 in premarket trading.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store